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The high incidence of acute infections known 
to occur in pregnant women contrasts with the 
relative rarity of fetal damage and attests to 
the efficiency of the mechanisms by which the 
fetus is protected in utero. 
The events shown in Fig. 1 summarize some 
of the obstacles which a virus must overcome in 
order to reach the fetus and produce defects. An 
effective exposure is required to allow the virus 
to multiply locally in the maternal tissues at the 
portal of entry. If a viremic phase results the ,.Virus 
becomes disseminated and the placent~ riia:Y' be 
infected; depending on the type of infottion, 
placental damage may or may not result. If the virus 
successfully crosses the placental barrier, the fetus 
may become infected either by way of fetal viremia 
or by contiguous spread through the membranes. 
Since maternal viremia is necessary to initiate this 
chain of events, the fetus is naturally protected 
against vin1ses which seldom invade the blood 
stream. Most of the viruses causing respiratory 
diseases fall into this category. The maternal im-
munologic system provides significant protection 
by circulating antibodies stimulated by earlier nat-
ural or vaccine induced infection. Even if the mother 
is susceptible and the infection is associated with 
viremia, the virus may still be effectively stopped 
by the placental barrier; this has been shown to 
occur commonly in both rubella and cytomegalo-
virus (CMV) infection. If, on the other hand, the 
virus reaches the fetus, to produce a teratogenic 
effect the virus must have a delicately controlled 
pathogenicity allowing a chronic infection to be 
established compatible with a period of continued 
growth and development. Only two or perhaps 
three human viruses have been documented to 
have the ability to produce such infections. These 
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Fig. I-Events leading to fetal infection and disease. 
include rubella virus, human cytomegalovirus, and, 
possibly, herpesvirus hominis (herpes simplex virus). 
Of these three hutrian viruses, the teratogenic 
effeCts of herpes simplex virus are the least 
documented. There are 5 reports in the literature 
suggesting that genital herpes infections acquired 
early in pregnancy may be associated with con-
genital malformations. Defects seen in these .5 infants 
included microcephaly, microphthalmus, and char~ 
ioretinitis. Skin lesions were present either at 
birth or soon thereafter in 3 cases arid encephali-
tis was present in 1 instance. Investigation of the 
infants with microcephaly for other possible in-
fectious etiologies includirig cytomegalovirus and 
toxoplasmosis infection gave negative results. The 
association of herpes simplex virus with eye and 
central nervous system (CNS) defects in these cases 
is highly suggestive that this virus may on occasion 
be teratogenic; the role of herpes simplex virus in 
this regard deserves further investigation (Nahmias, 
et al, 1970). 
As the result of a decade of intensive interest, 
rubella represents the most adequately studied 
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congenital infection producing fetal defects (Krug-
man, 1969). It also represents the only teratogenic 
virus infection currently controllable through the 
use of vaccine. 
Rubella is recognized to occur every year in 
sporadic outbreaks covering restricted areas. Since 
1928 major epidemics of the di~ease involving the 
entire country or large sections of the country have 
occurred at 6- to 9-year intervals. Rubella shows 
the same prominent seasonal pattern of other dis-
eases transmitted by the · respiratory route. The 
maximum incidence of the disease occurs during the 
winter and spring months, with very low rates in 
summer and fall. In a nonepidemic year, it has 
been estimated that the occurrence of rubella in 
pregnant women is in excess of 8/10,000 preg-
nancies. In an epidemic year, this rate may increase 
30 to 40 times. · 
The clinical features of natural rubella virus 
infection vary from the clinically inapparent to 
an illness of sufficient severity to be confused 
with measles. Children before the age of puberty 
tend to have a mild illness consisting typically 
of 3 days of low-grade fever, seldom exceeding 
101 °F, rash, and generalized lymphadenopathy. 
Nodes are especially prominent in the posterior 
cervical region. In adults, particularly women, 
the illness is often more severe. The earliest evi-
dence of infection is lymphadenopathy. The nodes 
may be tender and the enlargement often persists 
for several weeks after the onset of symptoms. 
The rash is variable in appearance. Ordinarily, 
it first becomes apparent on the face and spreads 
rapidly to the trunk and upper extremities. It may 
have begun to fade on the face by the time it be-
comes fully developed on the lower extremities. 
Prominent respiratory tract symptoms do not occur. 
Women with . rubella sometimes also complain 
of headache, malaise, myalgia, painful gums, and 
paresthesias, particularly of the hands. 
Rubella is the only viral infection in this 
country which is frequently associated with arthr-
algia and arthritis. Age and sex have a marked effect 
on the frequency and severity of these symptoms. 
In a recent retrospective survey following an 
epidemic, 25 % of prepubertal children ~xperienced 
joint-related symptoms. After puberty there was a 
sharp increase in the . incidence of arthralgia and 
arthritis, and with increasing age between menarche 
and menopause the frequency and severity of in-
volvement increased progressively. Commonly the 
joint symptoms followed the rash by several days, 
although in some instances arthritis preceded the 
rash . or was delayed until several weeks after the 
onset "'of 'infection. The joints involved, in order of 
frequency, were the proximal interphalangeal 
joints, the knees, wrists, ankles, and the meta-
tarsophalangeal joints. Symptoms ordinarily sub-
sided in 1 to 14 days but some patients, notably 
older women, experienced recurring symptoms 
lasting for a year or more. Even in such instances 
symptoms have cleared and there has been no 
residual deformity. There is no evidence that these 
reactions predispose to the development of chronic 
arthritis. 
· ·In the typical case, virus may be recovered 
from blood and respiratory secretions one to one 
and a half weeks prior to the onset of rash. 
Viremia disappears shortly after the onset of rash 
in association with the appearance of circulating 
antibodies. Presence of virus in the respiratory 
tract diminishes more slowly; virus may continue to 
be recoverable for several weeks. Neutralizing 
and hemagglutination-inhibiting (HAI) antibodies 
develop promptly after the exanthem appears and 
persist for years, probably for life. The CF 
antibody response is slightly delayed and may 
decline over · a period of years. The widespread 
availability of the HAI test has made the rubella 
serodiagnosis of critical cases available to every-
one. Establishing an accurate diagnosis is nowhere 
more important than in the instance when a preg-
nant woman is exposed to rubella. Under such 
circumstances, an initial serum specimen should 
be obtained as soon as possible after exposure and 
tested for antibodies to determine the immune 
status of the patient. Subsequent sa.mples should 
be collected in early convalescence · if disease 
develops and in asymptomatic patients at 4 and 
6 weeks after exposure. These later samples tested 
in parallel with the earlier · specimen will document 
if infection has occurred. 
In 1940, a communication appeared in a prom-
inent medical journal protesting interest in rubella 
as inappropriate since it was "an entirely incon-
sequential disea.se." This misconception was laid to 
rest within the next year by the astute observations 
of an Australian ophthalmologist. This was the con-
tribution of the late Sir Norman Gregg, who opened 
the field of viral teratogenesis as a result of his 
discovery of the association between maternal 
rubella, congenital cataract, and heart defects. 
Over the years since Gregg's original observations, 
it has become apparent that virtually any organ 
system of the developing fetus may be damaged. 
The fetal infection may be severe enough to 
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cause spontaneous abortion or stillbirth. Congenital 
involvement often present in the newborn period 
included deafness, heart disease, retardation, men-
ingoencephalitis, microcephaly, eye defects, in-
cluding congenital cataract, retinopathy and glau-
coma, purpura, anemia, hepatosplenomegaly with 
hepatitis an~ jaundice, pneumonitis, · and bone 
lesions. 
The earlier in pregnancy maternal rubella 
occurred, the more likely jt was that the defects 
would be multiple and severe. Follow-up data 
indicated that infectjon. during the nrst 2 months of 
gestation was associated wjth the highest incidence 
of heart, eye, and CNS defects; fetuses infected in 
the 3rd month had significantly fewer heart and eye 
defects. All types of malformations declined in 
those babies who had been infected during the 
4th month (Cooper, et al, 1969). It ha~ been esti-
mated that the chances of anomalies when ma-
ternal infection occurs during the first month is in 
excess of 50%, in the second month about 22%, 
and in the 3rd through 5th months, 6% to 10%. 
In the pathogenesis of congenital rubella, 
viral invasion of the placenta occurs during the 
peri9d of materna·l viremia. Replication of virus 
in the placenta produces focal areas of mild in-
flammatory response and scattered damage of the 
endothelium of the chorionic blood vessels. Ex-
tension of the infection to the fetal circulation per-
mits the virus to reach the developing organs 
where a persistent infection ensues. This infection 
may be localized or widely disseminated throughout 
the fetal tissues. Virus shedding in pharyngeal se-
cretions and urine and the presence of virus in the 
tissues can be demonstrated throughout the neo-
natal period; in those infants with severe rubella 
defects, particularly, virus shedding may continue 
sporadically int~ the second year. The presistence 
of virus is of epidemiological importance since 
rubella infected infants can transmit their infectiOn 
to nursery personnel and other contacts; thus · it 
is important to limit the contact of such infants 
with pregnant women in the hospital and after 
discharge; · 
Antibody responses in maternal rubella, as 
with most infectious diseases, consist of the early 
appearance of transient IgM antibody, promptly 
followed and eventually replaced by the IgG class 
of antibodies. It is the latter which are responsible 
for the long-term persisting rubella antibodies. 
The situation in the infected fetus is more complex. 
Maternal IgG is transplacentally transferred. The 
infected fetus begins to produce his own immune 
substances, in the form of IgM antibodies, at some 
period during the second trimester. At birth the 
titer of antibodies in maternal and infant sera is 
very nearly the same. The infant's antibodies are 
made up of both transplacental IgG and endogene-
ous IgM. As many as 80% of rubella infants will 
have an ·elevated IgM serum protein fraction dur-
ing the neonatal period. During the first year of 
life, passively acquired IgG declines. The pro-
duction of infant IgG appears during the early 
months of life, and late in the first year replaces 
IgM as the predominant rubella antibody. 
· At · the present time, short of therapeutic 
abortion, there are two methods for averting 
congenital rubella : ( 1) passive immunization of 
exposed pregnant women using commercially 
available immune serum globulin (gamma glo-
bulin); and (2) the use of live attenuated rubella 
vifus vaccine for active immunization of nonpreg-
nant subjects. 
Gamma globulin has been commonly used 
for many years for the prevention of rubella in-
fection in exposed pregnant women. The efficacy 
ofthis procedure has been a matter of controversy. 
There is no question that large doses of globulin 
given prior to exposure are effective in decreasing 
the incidence of infection and the clinical mani-
festations among those who acquire infection. In 
tfle ordinary circumstance in which globulin is 
used, however, exposure has already occurred 
several days earlier. In such cases the beneficial 
effect of globulin · is less well documented. In fact, 
~hildren with rubella syndrome defects have been 
born to mothers given appropriately timed ade-
quate doses of gamma globulin. Carefully performed 
virologic studies, designed to mimic the usual post-
exposure situation encountered clinically, failed to 
show protection against experimental infections, 
although there was some effect in diminishing the 
duration of viremia. From these data, it is obvious 
that globulin is unreliable as a measure for the 
prevention of congenital defects. On the other hand, 
it is impossible to be certain that globulin, through 
reducing the duration or level of viremia, might 
not have some effect in reducing the risk of fetal 
infection. On this basis, and because it represents 
the only currently available measure which might be 
of help in this situation, our feeling is that the 
continued use of large doses (20 ml of gamma 
globulin) is justifiable in circumstances where in-
terruption of pregnancy is not desired. 
Live rubella vaccines are prepared in cell cul-
tures and induce immunity by producing a modi-
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fied rubella infection in susceptible persons (Meyer 
and Parkman, 1971). The 3 vaccines currently 
available are produced in duck embryo cells by 
Merck, Sharp, and Dohme (Meruvax®), in canine 
renal cells by Philips Roxane, Inc. (marketed by 
them as rubella virus vaccine, live) and by Parke 
Davis and Co. as Rubelogen®, and in rabbit renal 
cells by Smith Kline and French, Inc. (Cendevax®). 
In children, vaccine induced infections are usually 
asymptomatic, while adults may develop rubella 
like symptoms. Such symptoms may consist of 
an evanescent rash, lymphadenopathy, and tran-
sient peripheral nerve and joint involvement. The 
most troublesome complaints have been related 
to occurrence of arthralgias, arthritis, and pares-
thesias; these symptoms follow a pattern of dis-
tribution similar to that seen in the natural 
disease. They appear within 3 to 5 weeks after 
immunization, but on occasion may be delayed until 
8 weeks postvaccination. Reaction rates in women 
of childbearing age range from 10% to 60% and 
as in the natural disease are in part related to the 
age of the woman; reaction rates have been highest 
in the older age groups. The immunogenicity of the 
vaccine used also affects the likelihood of reac-
tions. The canine renal cell prepared vaccine which 
produces higher antibody levels was also responsible 
for higher reaction rates than vaccines prepared in 
duck or rabbit cells. The joint manifestations are 
usually mild; however, occasionally a patient may 
continue to have residual subjective complaints last-
ing for weeks or months. Persons with arthritic 
manifestations have not shown the development 
of later chronic joint disease. 
Rubella vaccines stimulate antibodies in 95 % 
to 100% of recipients between the 2nd and 4th 
weeks postvaccination. Thus far, these antibodies 
have been shown to persist without significant 
decline throughout the 5-year period of observa-
tion since the earliest vaccinations were performed. 
In the United States, efforts of mass vaccina-
tion programs have been directed toward the im-
munization of children. This approach is designed 
to reduce the opportunities for spread of virus 
by decreasing the susceptible childhood popula-
tion most responsible for initiating and maintaining 
epidemic rubella. At the same time, the desirability 
of providing protection for the susceptible adult 
women is also recognized. Immunization of this 
group presents special problems. Arthritic reac-
tions are more common in this age range; most im-
portant, however, is the risk of immunizing women 
in unrecognized early pregnancy or women who may 
become pregnant immediately after vaccination. In 
such situations, it has been shown that in susceptible 
women the attenuated virus can produce chronic 
placental infection which may be transmitted to 
the fetus. Generally, when vaccinations have been 
performed early in gestation, therapeutic abortion 
has been performed. Too few pregnancies have 
proceeded to term to determine the possible conse-
quences of fetal infection with vaccine virus. Thus 
it is highly important when vaccinating adult wo-
men, to insure that the patient is not pregnant 
and will not become pregnant for at least two 
months after immunization. Pretesting of women 
for HAI antibodies is recommended and will ex-
clude the necessity for using vaccine in immune 
women. 
If vaccines are used extensively and if the 
immune status of the population can be main-
tained at a high level, it seems possible that rubella 
control can be achieved. 
In comparison with the abundance of infor-
mation available about rubella, knowledge of the 
epidemiology and pathogenesis of congenital CMV 
infections is limited. Thirty to sixty percent of 
childbearing age women have detectable anti-
bodies. Infection during the reproductive years 
may be quite common. Serologic responses occurred 
in 3 % to 5 % of pregnant women in two urban 
centers studied. Information is not currently avail-
able concerning the frequency with which maternal 
infection is transmitted to the fetus. It is also 
unclear what proportion of fetal infections are 
( 1) inapparent, (2) silent at birth but produce 
clinical manifestations later, or (3) result in classical 
cytomegalic inclusion disease. The reason for this 
poor documentation is in part attributable to the 
fact that maternal infections are subclinical. Rarely 
acute CMV infection in the adult may mimiC in-
fectious mononucleosis. Diagnosis of maternal CMV 
infection by virus recovery is hampered by the 
observation that virus may be shed in the urine 
for periods up to 2 years following initial infection; 
thus recovery of virus from a pregnant woman does 
not necessarily indicate acute disease. 
The occurrence of the majority of congenital 
CMV infection in babies born to young primiparous 
mothers, suggests that intrauterine infection is most 
commonly acquired by the fetus during the viremic 
phase of primary maternal CMV infection. Fetal 
infection may occur in the first trimester (Davis, 
et al, 1971) and perhaps later in pregnancy as well. 
As in rubella, it has been shown that placental in-
fection may occur without infection of the fetus . 
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Congenital CMV infection in 2 siblings born 
within 8 months of one another has been recently 
reported (Emil, et al, 1970). The possibility of 
such an occurrence should not be overlooked in 
the follow-up of women who have borne a CMV 
affected child. 
Adding to the complexity of the CMV prob-
lem is the observation that multiple antigenic vari-
ants of the virus exist; the significance of this varia-
tion in the virus for immunity and the possibility of 
reinfection is unknown. 
The features of classical congenital cytomegalic 
inclusion disease include, like rubella, defects in 
CNS, eye, and hepatic and bone marrow func-
tion. Microcephaly and hydrocephaly, encephalitis, 
cerebral calcifications, convulsive disorders, chorio-
retinitis, blindness, hepatosplenomegaly with jaun-
dice, thrombocytopenia with petechiae, anemia, 
and interstitial pneumonia all can occur. Unlike 
the rubella syndrome, cataracts and heart defects 
are not seen. 
As in congenital rubella, virus can be re-
covered from throat, urine, and blood of affected 
live born children and from multiple tissues of 
aborted or stillborn fetuses. Virus recovery from 
clinical specimens, unless accomplished in the im-
mediate newborn period, cannot be taken as certain 
indication of an etiologic relationship between 
defects and CMV infection since these viruses can 
be recovered with some frequency from urine of 
asymptomatic children. The demonstration of ele-
vated serum IgM and the persistent occurrence 
of specific CMV IgM antibodies in the serum of 
newborn infants provides convincing evidence of 
intrauterine infection (Sever and White, 1968; 
Alford, et al, 1967). 
Aside from the experimental use of chemo-
therapeutic agents which inhibit replication of DNA 
viruses in children with the congenital disease, no 
methods of prevention or treatment are currently 
available. 
What new developments are likely to occur 
which might be important from the standpoint 
of congenital infections? Several recent reviews 
have explored the status of other viral agents in 
producing abortions, stillbirths, and neonatal dis-
ease. It has been speculated on the basis of 
epidemiologic studies that other agents including 
varicella, vaccinia, mumps, influenza, and measles 
viruses may possibly induce fetal defects (Sever 
and White, 1968; Hardy, 1965). The etiologic re-
lationship of these viruses with congenital defects 
are not in hand, but with additional study might 
yet be proven. Perhaps other mechanisms than 
those active in rubella and CMV infections will 
be shown important. An even more interesting 
possibility relates to the cancer virus field. Impres-
sive evidence is available indicating that many 
tumors of amphibians, birds, rodents, and cats are 
caused by viruses. The study of animal model sys·· 
terns in chickens and mice indicates that RNA 
leukemia viruses may be transmitted "vertically," 
that is, directly from mother to embryo. The inci-
dence of malignant disease in the congenitally in-
fected animal is higher than that seen in the adult 
host infected by contact. Could such situations 
exist in man? Enough parallels exist between the 
human and animal diseases to make this a tantaliz-
ing possibility. Perhaps as techniques for search-
ing out human oncogenic viruses become more 
sophisticated, similar agents may one day be rec-
ognized as causing highly important congenitally 
acquired infections. 
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